About this Immunology and Microbiology article

HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19 by Chiara Ripamonti; Valeria Spadotto; Pietro Pozzi; Andrea Stevenazzi; Barbara Vergani; Mattia Marchini; Giovanni Sandrone; Emanuele Bonetti; Luca Mazzarella; Saverio Minucci; Christian Steinkühler; Gianluca Fossati is a Immunology and Microbiology article available to read on EtoBox.

The COVID-19 pandemic has had a devastating impact worldwide and has been a great challenge for the scientific community. Vaccines against SARS-CoV-2 are now efficiently lessening COVID-19 mortality, although finding a cure for this infection is still a priority. An unbalanced immune response and the uncontrolled release of proinflammatory cytokines are features of COVID-19 pathophysiology and contribute to disease progression and worsening. Histone deacetylases (HDACs) have gained interest in immunology, as they regulate the innate and adaptative immune response at different levels. Inhibitors of these enzymes have already proven therapeutic potential in cancer and are currently being investigated for the treatment of autoimmune diseases. We thus tested the effects of different HDAC inhibitors, with a focus on a selective HDAC6 inhibitor, on immune and epithelial cells in __in vitro__ models that mimic cells activation after viral infection. Our data indicate that HDAC inhibitors reduce cytokines release by airway epithelial cells, monocytes and macrophages. This anti-inflammatory effect occurs together with the reduction of monocytes activation and T cell exhaustion and with an i

Author

Chiara Ripamonti; Valeria Spadotto; Pietro Pozzi; Andrea Stevenazzi; Barbara Vergani; Mattia Marchini; Giovanni Sandrone; Emanuele Bonetti; Luca Mazzarella; Saverio Minucci; Christian Steinkühler; Gianluca Fossati

Publisher

Frontiers Media SA

Published

2022

Language

EN

Field

Immunology and Microbiology (Life Sciences)